Oncolytics Biotech (ONCY) Receivables - Other (2016 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Receivables - Other of $573000.0 for Q4 2025, up 1077.13% year-over-year from $48677.7 in Q4 2024, and up 1360.31% quarter-over-quarter from $39238.3 in Q3 2025.
Oncolytics Biotech (ONCY) Receivables - Other (2016 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Receivables - Other for 10 consecutive years, with $573000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Receivables - Other rose 1077.13% year-over-year to $573000.0; the TTM figure through Dec 2025 stood at $573000.0 (up 1077.13% YoY), while the FY2025 annual figure was $573000.0, up 1119.15% from the prior year.
- Receivables - Other rose to $573000.0 in Q4 2025 per ONCY's latest filing, from $39238.3 in the prior quarter.
- Across five years, Receivables - Other topped out at $1.1 million in Q2 2024 and bottomed at -$65241.8 in Q3 2024.
- Historically, Receivables - Other has averaged $279044.4 across 5 years, with a median of $155086.8 in 2021.
- Annual changes were most pronounced in 2024 — Receivables - Other sank 113.88% — and 2025, when it surged 1077.13%.
- Oncolytics Biotech's Receivables - Other stood at $687029.0 in 2021, then slumped by 44.13% to $383822.2 in 2022, then sank by 97.13% to $11018.0 in 2023, then soared by 341.8% to $48677.7 in 2024, then soared by 1077.13% to $573000.0 in 2025.
- Business Quant data shows ONCY's Receivables - Other at $573000.0 in Q4 2025, $39238.3 in Q3 2025, and $51963.3 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Oncolytics Biotech | 99.68 Mn | 99.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.21 Mn |
| Jun 30, 2026 | 1.21 Mn |
| Dec 31, 2025 | 573,000.00 |
| Dec 31, 2025 | 573,000.00 |
| Sep 30, 2025 | 39,238.29 |
| Sep 30, 2025 | 39,238.29 |
| Jun 30, 2025 | 51,963.30 |
| Jun 30, 2025 | 51,963.30 |
| Mar 31, 2025 | 62,025.57 |
| Mar 31, 2025 | 62,025.57 |
| Dec 31, 2024 | 48,677.74 |
| Dec 31, 2024 | 48,677.74 |
| Sep 30, 2024 | -65,241.75 |
| Sep 30, 2024 | -65,241.75 |
| Jun 30, 2024 | 1.15 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Mar 31, 2024 | 75,695.55 |
| Mar 31, 2024 | 75,695.55 |
| Dec 31, 2023 | 11,018.03 |
| Dec 31, 2023 | 11,018.03 |